Literature DB >> 10667605

Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.

J Rak1, Y Mitsuhashi, C Sheehan, A Tamir, A Viloria-Petit, J Filmus, S J Mansour, N G Ahn, R S Kerbel.   

Abstract

A possible link between oncogenes and tumor angiogenesis has been implicated by the finding that expression of various oncogenes, particularly mutant ras, can lead to a marked induction of a potent paracrine stimulator of angiogenesis, vascular endothelial growth factor (VEGF). We sought to determine how oncogenic ras induction of VEGF is mediated at the molecular level and whether the mechanisms involved differ fundamentally between transformed epithelial cells and fibroblasts. Our results suggest that in a subline (called RAS-3) of immortalized nontumorigenic rat intestinal epithelial cells (IEC-18) that acquired a tumorigenic phenotype upon transfection of mutant ras, up-regulation of VEGF occurs in the absence of an autocrine growth factor circuit. The expression of VEGF mRNA and protein by RAS-3 cells was strongly suppressed in the presence of LY294002, an inhibitor of phosphatidylinositol 3'-kinase, but remained largely unaffected in the same cells treated with an inhibitor (PD98059) of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MKK/MEK-1). This is consistent with the observation that overexpression of a constitutively activated mutant of MEK-1 (AN3/ S222D) in the parental IEC-18 cells did not result in up-regulation of VEGF production. The impact of mutant ras on VEGF expression was also significantly amplified at high cell density, conditions under which RAS-3 cells became less sensitive to LY294002-induced VEGF down-regulation. In marked contrast to cells of epithelial origin, ras-transformed murine fibroblasts (3T3RAS) up-regulated VEGF in a manner that was strongly inhibitable by MEK-1 blockade (ie. treatment with PD98059), whereas these cells were relatively unaffected by treatment with the phosphatidylinositol 3'-kinase inhibitor LY294002. In addition, VEGF was up-regulated by 2-3-fold in NIH3T3 cells overexpressing mutant MEK-1. Collectively, the data suggest that the stimulatory effect of mutant ras on VEGF expression is executed in a nonautocrine and cell type-dependent manner and that it can be significantly exacerbated by physiological/ environmental influences such as high cell density.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10667605

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

1.  Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.

Authors:  Guido Bocci; Giulio Francia; Shan Man; Jack Lawler; Robert S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-15       Impact factor: 11.205

2.  G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.

Authors:  Ondrej Fiala; Tomas Buchler; Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Vit Martin Matejka; Lubos Holubec; Jana Kulhankova; Zbynek Bortlicek; Marie Bartouskova; Vaclav Liska; Ondrej Topolcan; Monika Sedivcova; Jindrich Finek
Journal:  Tumour Biol       Date:  2015-12-10

Review 3.  Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights.

Authors:  Kimberly Ng; Ryan Kim; Santosh Kesari; Bob Carter; Clark C Chen
Journal:  J Neurooncol       Date:  2011-10-16       Impact factor: 4.130

4.  ERKs activation and calcium signaling are both required for VEGF induction by vanadium in mouse epidermal Cl41 cells.

Authors:  Jingxia Li; Qiangsong Tong; Xianglin Shi; Max Costa; Chuanshu Huang
Journal:  Mol Cell Biochem       Date:  2005-11       Impact factor: 3.396

Review 5.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

6.  Reactive oxygen generated by Nox1 triggers the angiogenic switch.

Authors:  Jack L Arbiser; John Petros; Robert Klafter; Baskaran Govindajaran; Elizabeth R McLaughlin; Lawrence F Brown; Cynthia Cohen; Marsha Moses; Susan Kilroy; Rebecca S Arnold; J David Lambeth
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 7.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

Review 8.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

9.  Transformation by oncogenic Ras expands the early genomic response to transforming growth factor beta in intestinal epithelial cells.

Authors:  Carl E Allen; Jianguo Du; Bo Jiang; Qin Huang; Adam J Yakovich; John A Barnard
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

10.  Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

Authors:  Yu-Wen Zhang; Yanli Su; Olga V Volpert; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.